Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BG00012 (DMF) Clear all

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: ALKS 8700, Dimethyl Fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 57
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Multiple Sclerosis
Interventions: Rebif (IFN β-1a subcutaneous three times per week), Tecifdera (dimethyl fumarate); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: BG00012 (DMF); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 37
States / cities: Cullman, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 33 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more

Conditions: Multiple Sclerosis
Interventions: Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug; Procedure · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: BG00012 (DMF) (Tecfidera®.); Drug
Lead sponsor: Multiple Sclerosis Center of Northeastern New York; Other
Eligibility: 25 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Latham, New York

Conditions: Multiple Sclerosis
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 5,487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 168
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 140 more

Conditions: Healthy
Interventions: BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Adult Brain Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
Interventions: Dimethyl Fumarate, Temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Multiple Sclerosis
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 15
States / cities: Gilbert, Arizona • Phoenix, Arizona • Long Beach, California + 12 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: natalizumab, dimethyl fumarate; Biological · Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 43
States / cities: Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 40 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscon, Arizona • Los Angeles, California + 57 more

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Rebif, Tecfidera; Drug
Lead sponsor: IMS HEALTH GmbH & Co. OHG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 22
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Savannah, Georgia + 19 more

Conditions: Multiple Sclerosis (MS) Relapsing Remitting
Interventions: Vumerity, Tecfidera; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers
Interventions: Test product, Reference product; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Early Highly Effective Therapies Group, Escalation Therapies Group; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more

Conditions: Systemic Sclerosis, Pulmonary; Hypertension
Interventions: Dimethyl Fumarate (DMF), Placebo Oral Tablet; Drug
Lead sponsor: Robert Lafyatis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Multiple Sclerosis
Interventions: dimethyl fumarate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Homewood, Alabama • Newport Beach, California • Atlanta, Georgia + 6 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Multiple Sclerosis
Interventions: Bafiertam, Tecfidera; Drug
Lead sponsor: Banner Life Sciences LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Foxborough, Massachusetts

Conditions: Multiple Sclerosis
Interventions: Dimethyl fumarate; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Multiple Sclerosis
Interventions: dimethyl fumarate, montelukast, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 50
States / cities: Jonesboro, Arkansas • Carmichael, California • La Jolla, California + 46 more

Conditions: Multiple Sclerosis
Interventions: Dimethyl fumarate; Drug
Lead sponsor: Virginia Simnad; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Kirkland, Washington

Search by objective public record fields.

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

Dimethyl Fumarate (DMF) Observational Study

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Tecfidera Slow-Titration Study

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)

Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

Tecfidera Lymphocyte Chart Review

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Tecfidera and MRI for Brain Energy in MS

Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera

Impact of Tecfidera on Gut Microbiota